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The recent discovery that the Nipah virus (NiV) fusion protein (F) is activated by endosomal cathepsin L raised the question if NiV utilize pH-
and protease-dependent mechanisms of entry. We show here that the NiV receptor ephrin B2, virus-like particles and infectious NiV are
internalized from the cell surface. However, endocytosis, acidic pH and cathepsin-mediated cleavage are not necessary for the initiation of
infection of new host cells. Our data clearly demonstrate that proteolytic activation of the NiV F protein is required before incorporation into
budding virions but not after virus entry.
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The highly pathogenic Nipah virus (NiV) was isolated in
1999 after an outbreak of fatal encephalitis among pig farmers
in Malaysia and Singapore (Chua, 2003). Old World fruit bats
of the genus Pteropus have been identified as the natural host of
NiV (Yob et al., 2001). Because of several unique genetic and
biological characteristics NiV and the closely related Hendra
virus form the new genus Henipavirus within the Paramyxo-
viridae family (Harcourt et al., 2000; Wang et al., 2000). Due to
their broad host range and the high mortality rates associated
with infection, the henipaviruses have been classified as
Biosafety Level 4 (BSL4) agents.
As most paramyxoviruses, NiV encodes for two surface
glycoproteins which are essentially required for the virus entry
process. After binding of the G protein to the cellular surface
receptor, the fusion protein F mediates fusion of the viral and
cellular membranes. Recently, ephrin B2 (EB2) has been shown
to function as main entry receptor for NiV (Bonaparte et al.,
2005; Negrete et al., 2005). EB2 is a transmembrane-anchored
ligand of the receptor tyrosine kinases EphB2, EphB3 and
EphB4, and plays a critical role in embryonic patterning, axon
guidance and angiogenesis (Adams, 2002; Kullander and Klein,⁎ Corresponding author. Institut für Virologie, Hans-Meerwein-Str. 2, D-35043
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doi:10.1016/j.virol.2008.02.0192002). As EB2 is predominantly expressed on endothelial cells
and neurons (Adams, 2002), this is consistent with the known
cellular tropism for NiV (Wong et al., 2002).
For successful virus entry into EB2-expressing cells, a
fusion-active NiV F protein is required. As other paramyxoviral
F proteins, the NiV F protein is synthesized as inactive pre-
cursor and is cleaved by host cell proteases into the subunits
F1 and F2. Thereby the hydrophobic fusion peptide at the
N-terminus of F1 is released. Interestingly, the recently uncovered
proteolytic cleavage mechanism used by henipavirus F proteins
differs fundamentally from that utilized by related viruses. Other
paramyxoviral fusion proteins are either processed by extra-
cellular trypsin-like proteases after reaching the cell surface or
after being incorporated into budding viruses, or they are cleaved
by the Golgi protease furin during transport along the secretory
pathway (Klenk and Garten, 1994). Because most of the F
proteins in virus particles are cleaved and fully fusion competent,
paramyxoviruses can enter new host cells via fusion of the viral
membrane and the plasma membrane at neutral pH (Earp et al.,
2005). However, henipavirus F proteins are neither cleaved by
trypsin- nor furin-like proteases but must be activated by
cathepsin L (CTSL) within an acidic endosomal compartment
(Diederich et al., 2005;Meulendyke et al., 2005; Pager andDutch,
2005; Pager et al., 2006). Cleavage efficiency strongly depends
on endocytic activity and the expression level of CTSL which
varies markedly in different cell types. Even though some cleaved
F protein is expressed on the surface of all cells tested so far, the
Fig. 1. Endocytosis of EB2 in different cell lines. EB2-expressing cells (Vero,
MDCK, PAEC, and HeLa) were incubated with EphB4/Fc for 1 h at 37 °C to
allow binding and endocytosis to proceed. Surface-remained EphB4/Fc was
stained with a rhodamine-conjugated anti-human IgG antibody (surface). After
fixation and permeabilization, internalized EphB4/Fc was detected by a FITC-
conjugated secondary antibody (intracellular).
392 S. Diederich et al. / Virology 375 (2008) 391–400percentage of cleaved NiV F protein is generally low (Moll et al.,
2004a; Diederich, unpublished). Thus, most of the F protein
present on the plasma membrane is not fusion competent. This
raised the question if NiV particles released from infected cells
contain sufficient amounts of activated F protein to enter a new
host cell directly by pH-independent fusion with the plasma
membrane, or if virus endocytosis and subsequent F cleavage by
endosomal CTSL are essential for the entry process. The aim of
this study was to clearly define which steps of the NiV replication
cycle require endocytic and proteolytic processes.
Results
The NiV receptor EB2 is endocytosed in different cell types
The idea of NiVentry via receptor-mediated endocytosis was
supported by the recent report that the NiV receptor EB2 is
internalized from human endothelial cells (Korff et al., 2006).
To analyze if EB2 endocytosis is a general phenomenon in NiV-
susceptible cells, we performed a qualitative uptake assay using
Vero, MDCK, PAEC or HeLa cells which have been transfected
with an EB2-encoding expression plasmid. After addition of
recombinant mouse EphB4/Fc, a soluble EB2 receptor fused to
the Fc region of human IgG, cells were incubated at 37 °C for
1 h to allow binding of EphB4 and co-endocytosis of EB2 and
EphB4/Fc. Surface-remained EphB4/Fc was then stained with a
rhodamine-conjugated secondary antibody at 4 °C. After
permeabilization, internalized EphB4/Fc was visualized by
incubation with a FITC-conjugated secondary antibody. Fig. 1
clearly shows that numerous fluorescent intracellular vesicles
(green) were found in all EB2-expressing cells indicating that
the EB2 receptor is efficiently endocytosed in NiV-susceptible
cells.
G-containing VLPs and NiV particles are internalized from the
surface of EB2-expressing cells
To determine if NiV particles bound to EB2-expressing cells
are also internalized, we made use of the recent finding that the
NiV G protein is released in virus-like particles (VLPs) upon
single expression (Patch et al., 2007). The G-containing VLPs
resemble infectious NiV particles in shape and size (not shown)
and can therefore be utilized to study G-mediated attachment
and uptake into host cells outside of the BSL4 facility. VLPs
were generated by transfection of 293T cells with the NiV Gtag
gene. At 72 h post transfection, supernatants were clarified by
low-speed centrifugation and pelleted through a 20% sucrose
cushion. VLP-containing pellets were resuspended and added to
EB2-expressing cells in combination with an antibody directed
against the HA-tag. After 1 h at either 4 °C or 37 °C, surface-
bound antibodies were stained with a FITC-conjugated
secondary antibody at 4 °C. After permeabilization, internalized
VLPs were visualized with a rhodamine-conjugated secondary
antibody and cell nuclei were counterstained with DAPI.
Merged pictures of the FITC, rhodamine and DAPI fluorescence
channels are shown in Fig. 2A. As expected, no intracellular
VLPs could be detected in the sample incubated at 4 °C (Fig. 2A,control-4 °C). In contrast, a substantial amount of VLPs was
found within the cells (red dots) if endocytosis was allowed at
37 °C (Fig. 2A, control-37 °C). When we performed the VLP
uptake assay in the presence of 0.45 M sucrose which is known
to inhibit endocytic uptake in general, internalization was clearly
inhibited (Fig. 2B, + sucrose). Many VLPs had bound to the
surface of sucrose-treated cells (green dots), but intracellular
VLPs were found less frequently. In order to reveal the endocytic
pathway required for VLP uptake, either 25 µM chlorpromazine,
an inhibitor of clathrin-dependent internalization, or 5 mM
β-methyl-cyclodextrin (MCD), an inhibitor of caveolae-
dependent endocytosis, was added prior and during uptake of
the VLPs. Chlorpromazine had basically no negative effect on
the internalization indicating that clathrin-mediated endocytosis
is not involved (Fig. 2B, + chlorpromazine). In contrast, MCD
which removes membrane cholesterol and disrupts lipid rafts
thereby preventing uptake via caveolae, markedly inhibited VLP
endocytosis (Fig. 2B, + MCD). To quantify the effect of the
inhibitors on VLP uptake, the number of internalized VLPs in 40
randomly chosen cells of each sample was counted and averaged.
When VLP uptake in untreated cells incubated at 37 °C (Fig. 2B,
control-37 °C) was set at 100%, chlorpromazine inhibited
Fig. 2. VLP- and virus-uptake assays. (A) Vero cells were incubated for 1 h at 4 °C (control-4 °C) or at 37 °C (control-37 °C) with purified NiV Gtag-containing VLPs
in combination with a monoclonal antibody directed against the HA-tag. Surface-bound VLPs were visualized by incubation with FITC-conjugated anti-mouse IgG
antibodies at 4 °C. After permeabilization with methanol–acetone, intracellular VLPs were stained with a rhodamine-conjugated secondary antibody. Nuclei were
visualized by DAPI staining. Merged pictures of the DAPI, FITC and rhodamine fluorescence channels are shown. (B) Cells were preincubated for 30 min at 37 °C
with the following endocytosis inhibitors: 0.45 M sucrose (sucrose), 25 µM chlorpromazine (chlorpromazine) or 5 mM β-methyl-cyclodextrin (MCD). Incubation
with VLPs and HA-tag antibody was performed for 1 h at 37 °C in the presence or absence of the inhibitors. Surface-bound and intracellular VLPs were stained as
described above. (C) Vero cells were incubated with infectious NiV particles for 2 h at 4 °C. After incubation with anti-NiV serum for 30 min on ice, cells were either
shifted to 37 °C or kept at 4 °C for 20 min. Surface-bound and intracellular antibodies were visualized as described above.
Fig. 3. Effect of endocytosis inhibitors, NH4Cl, and cathepsin inhibitors on F protein
cleavage. Vero cells expressing the NiV F protein were radiolabeled with [35S]-
Promix for 10min andwere then incubated in chasemediumcontaining the indicated
inhibitors for 2 h. F proteins were immunoprecipitated from cell lysates, separated on
a 12% SDS gel under reducing conditions, and subjected to autoradiography.
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produced a 48% and 51% uptake inhibition, respectively. This
result suggests that internalized VLPs have entered the cells via
caveosomes. In agreement, internalization of EB2 was also sig-
nificantly reduced in the presence of sucrose and MCD (data not
shown).
To support the idea of endocytic particle uptake, we
performed an uptake assay using infectious NiV. For this, NiV
particles were concentrated and partially purified from infected
cell supernatants. Viruses were then adsorbed to Vero cells and
labeled with an anti-NiV serum at 4 °C. Subsequently, cells were
either shifted to 37 °C to allow endocytosis of surface-bound
virions, or were kept at 4 °C. Antibodies on the cell surface were
then detected by FITC-conjugated secondary antibodies and
internalized virus–antibody complexes were stained with
rhodamine-coupled secondary antibodies after cell permeabili-
zation. If cells were not shifted to 37 °C, no intracellular staining
was observed (Fig. 2C, 4 °C), but numerous intracellular
(red) viruses could be detected after incubation at 37 °C when
uptake of virus particles was allowed (Fig. 2C, 37 °C). This
demonstrates that a substantial portion of surface-bound NiV
particles can enter the cells via endocytosis. Together, these
findings supported the concept that NiV uptake by receptor-mediated endocytosis might be an additional or alternative route
of virus entry to fusion at the plasma membrane.
Endocytosis and cathepsin inhibitors efficiently prevent NiV F
protein cleavage
In order to investigate the efficacy of various drugs and in-
hibitors to interfere with NiV F cleavage in Vero cells, substances
394 S. Diederich et al. / Virology 375 (2008) 391–400either affecting endocytosis (sucrose, chlorpromazine, MCD), or
preventing acidification of the endosome (NH4Cl) or inhibiting
CTSL-mediated cleavage (E64d, CatLIII, CA074ME), were
assayed for their inhibitory effects on F protein cleavage. Here,
F-transfected Vero cells were metabolically labeled with [35S]-
cysteine and -methionine for 10 min and incubated for 2 h in the
absence or presence of different concentrations of the various
inhibitors. After cell lysis, F proteins were immunoprecipitated,
separated on a 12% SDS gel under reducing conditions, and
subjected to autoradiography. In Fig. 3, the results are shown for
the optimal inhibitor concentrations, thus the highest drug con-Fig. 4. Effect of inhibitor treatments during and after virus entry on NiV infection. (A
NiVat a MOI of 0.2. Cells were treated with the indicated inhibitors for 1 h prior infec
(control). Then, inhibitors and input virus were removed, cells were washed and furt
cells were incubated for 1 h on ice with a polyclonal anti-NiV serum and prima
(B) Inhibitor treatment after virus entry. After infection of Vero cells with NiV for
presence of the indicated inhibitors. At 24 h p.i., immunostaining was performed as de
the concentrations used in this experiment.centrations showing no cytotoxic effect within 2 h. Non-specific
inhibition of all endocytic processes by 0.45 M sucrose as well as
specific inhibition of clathrin-mediated endocytosis by 25 µM
chlorpromazine almost completely prevented proteolytic proces-
sing of F0 into F1 and F2. This confirms our previous findings in
MDCK cells that F cleavage depends on a tyrosine-dependent
motif in the cytoplasmic tail which mediates endocytosis via
clathrin-coated pits (Diederich et al; 2005). In contrast to
chlorpromazine treatment, addition ofMCD only slightly affected
F protein processing (Fig. 3, 5 mMMCD). This demonstrates that
caveolae-mediated endocytosis is not predominantly involved in) Inhibitor treatment before and during virus entry. Vero cells were infected with
tion and for 1 h at 37 °C during virus adsorption and entry, or were left untreated
her incubated in medium for 24 h at 37 °C. After fixation and permeabilization,
ry antibodies were detected with rhodamine-conjugated secondary antibodies.
1 h at 37 °C, cells were washed and then incubated in the absence (control) or
scribed above. There was no generalized toxicity effect of any of the inhibitors at
Table 1
Effect of endocytosis inhibitors, NH4Cl, and cathepsin inhibitors on the
production of infectious NiV






0.45 M sucrose 2.5×104 0
2 mM MCD 1.9×104 n.d.
5 mM MCD 1.2×104 n.d.
25 µM chlorpromazine 3×103 0
20 mM NH4Cl 3×10
4 1.2×102
50 µM CA074ME 2.4×104 1.2×102
20 µM CatLIII 1.8×104 0
Vero cells were infected with NiVat a MOI of 0.2. The inhibitors indicated were
either added 1 h prior infection and during virus entry for 1 h at 37 °C (Inhibitor
treatment during entry), or after removal of input virus at 1 h p.i. (Inhibitor
treatment post entry). At 24 h p.i., virus titers in the cell supernatant were
determined by the TCID50 method.
n.d. = not done.
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this endocytic pathwaywas found to be involved in EB2 andVLP
uptake and might therefore play a role in receptor-mediated NiV
uptake. When F protein cleavage was analyzed in the presence of
20mMNH4Cl, 20 µME64d, a general cysteine protease inhibitor,
50 µM CA074ME, an inhibitor of cathepsin B and L (Montaser
et al., 2002; Pager and Dutch, 2005), or 20 µM CatLIII, a CTSL-
specific inhibitor, cleavage was found to be completely prevented
(Fig. 3). This confirms that F activation in Vero cells depends on
low pH and CTSL.
Drugs inhibiting endocytosis, acidification of the endosome or
cathepsin-mediated cleavage do not affect NiV entry but later
replication steps
To finally test if endocytic uptake and/or pH-dependent
cathepsin-mediated processing within the endosomes are not
only required for processing of newly synthesized F proteins but
also for successful virus entry, NiV infections were carried out
in the presence of the different inhibitors. In these infection
experiments, the minimal, non-cytotoxic concentrations re-
quired for maximal cleavage inhibition determined before were
used. All drugs and inhibitors were added to Vero cells 1 h priorFig. 5. Effect of sucrose and NH4Cl treatment on influenza virus entry. Vero cells wer
incubated with the indicated inhibitors for 1 h prior infection and for 1 h during viru
residual virus attached to the cell surface was inactivated by acidic pH treatment. At
Primary antibodies were detected with rhodamine-conjugated secondary antibodiesinfection and were present during NiV infection at 37 °C.
Because most of the infectious NiV had bound and entered the
cells after 60 min and further incubation did not result in a more
efficient infection (not shown), non-bound viruses and inhi-
bitors were removed after 1 h of infection and cells were further
cultured with serum-free medium. At 24 h post infection (p.i.),
supernatants were taken for virus titration. To determine the
amount of infected cells and to visualize syncytium formation,
cells were immunostained using a polyclonal anti-NiV serum.
As shown in Fig. 4A, NiV infection in untreated cells (control)
induced extensive cell-to-cell fusion as indicated by the for-
mation of large multinucleated syncytia. Interestingly, neither
the addition of endocytosis inhibitors (0.45 M sucrose, 2 or 5
mM MCD, 25 µM chlorpromazine) nor treatment with 20 mM
NH4Cl, nor the addition of cathepsin B and L or CTSL-specific
inhibitors (50 µM CA074ME; 20 µM CatLIII) had an effect on
NiV infection. The amount and the size of syncytia were similar
to those in the control infection, and also the virus titers in the
cell supernatants did not substantially differ (Table 1, Inhibitor
treatment during entry). As a control, Vero cells were infected
with fowl plague virus (FPV) under the same conditions
because it is well established that entry and fusion of influenza
viruses absolutely depend on internalization and acidic pH
within endosomes (Marsh and Helenius, 1989). The finding that
FPV infection was drastically reduced when either endocytosis
(0.45 M sucrose) or acidification of the endosome (20 mM
NH4Cl) was prevented clearly demonstrated that virus entry can
be effectively hindered by the inhibitor treatments before and
during virus adsorption (Fig. 5).
To analyze if the inhibitors have an effect if added after virus
entry, Vero cells were infected with NiV for 1 h at 37 °C. After
removal of non-bound viruses, cells were further incubated with
serum-free medium containing the different inhibitors. Since
MCD is highly toxic, it could not be used for longer incubation
periods and was therefore not tested. At 24 h p.i., the outcome of
the infection was again monitored by immunostaining of the
infected cells and titration of the infectious virus in the super-
natants. As shown in Fig. 4B, inhibitors disrupting endocytic
uptake as well as inhibitors preventing cathepsin-mediated
proteolytic processing drastically reduced syncytium formation.
Release of infectious virions into the supernatant was also
significantly decreased (Table 1, Inhibitor treatment post entry).
To determine the number of initially infected cells in eache infected with FPVat a MOI of 0.01. Cells were either left untreated (control) or
s adsorption and entry. After washings to remove the inhibitors and input virus,
16 h p.i., cells were fixed and stained with a FPV-specific monoclonal antibody.
and nuclei were visualized by DAPI staining.
Fig. 6. F protein cleavage in purified NiV. Mock-sample and purified NiV were
subjected to SDS-PAGE under reducing conditions and analyzed by Western
blotting. Viral proteins were either detected with a polyclonal anti-NiV serum
(anti-NiV) or with NiV F-specific antibodies (anti-F).
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one initially infected cell) in ten randomly chosen microscopic
fields were counted and averaged. In mock-treated cells, we
found an average of 2.5 syncytia per microscopic field (200×
magnification). In inhibitor-treated cells, the mean number of
single NiV-positive cells ranged from 2.0 to 2.8. Thus, the
number of cells initially infected by NiV was very similar in all
infections. This again indicates that inhibitor treatments did not
interfere with virus entry and initial infection but solely pre-
vented virus spread via cell-to-cell fusion and the release of
infectious virus particles. Thus, endocytosis, acidic pH and
cathepsin-mediated cleavage are not important for the initiation
of a NiV infection in a new host cell but are only required during
late stages of infection for the activation of newly synthesized F
proteins.
Our findings imply that cell-free NiV particles contain
sufficient amounts of cleaved F protein to be fully infectious. To
check the amount of cleaved F protein in cell-free virions, we
purified NiV from cell supernatants. The virus preparation was
separated on a 12% SDS gel, blotted to nitrocellulose and either
probed with a polyclonal anti-NiV serum recognizing predomi-
nantly the N, P and G protein, or incubated with an F-specific
antiserum directed against the NiV F cytoplasmic tail, thus
specifically detecting F0 and F1. The western blot analysis
shown in Fig. 6 revealed that about 75% of the F protein in the
virus preparation was cleaved. This clearly confirms that F
cleavage occurs before incorporation into budding virions.
Discussion
The initial stages in infection of enveloped virions involve
attachment to cell surface receptors followed by fusion with
cellular membranes to release the viral nucleocapsids into the
cytoplasm. Receptor binding and low pH are known to be the
two main triggering mechanisms responsible for conformational
changes in the viral glycoproteins leading to virus–cell fusion.
For pH-independent viruses such as paramyxoviruses, structural
changes in the fusion protein occur through interaction with the
viral receptor (Lamb et al., 2006). For pH-dependent viruses
such as toga-, rhabdo-, alpha-, flavi- and orthomyxoviruses, low
pH triggers conformational changes in the fusion protein afterinternalization into endosomes (Jardetzky and Lamb, 2004;
Kielian and Rey, 2006). For endocytic uptake many different
pathways are used by these viruses including macropinocytosis,
phagocytosis, clathrin- and caveolae-mediated pathways and
some less-well defined routes called non-clathrin-, non-
caveolae-dependent pathways (Marsh and Helenius, 2006). An
additional pH- and endocytosis-dependent entry strategy has
been recently proposed for Ebola virus and SARS coronavirus
(SARS-CoV). These viruses enter a new host cell via endo-
cytosis followed by acid-dependent digestion by cathepsins to
accomplish the fusion competence of the viral glycoproteins
(Chandran et al., 2005; Kaletsky et al., 2007; Schornberg et al.,
2006; Simmons et al., 2005).
At least for coronaviruses, it is known that members of the
same virus family can use distinct pathways for fusion protein
activation and virus entry. Whereas SARS-CoV and mouse
hepatitis virus (MHV)-2 require uptake by endocytosis and
subsequent proteolysis by cathepsins (Qiu et al., 2006; Simmons
et al., 2005), infectious bronchitis virus only needs an acidi-
fication step (Chu et al., 2006) and theMHV-A59 strain or human
CoV NL63 can enter the cell by pH-independent fusion at the
plasma membrane (Huang et al., 2006; Qiu et al., 2006). The
finding that the NiV F protein must be activated by endosomal
proteases raised the possibility that NiV, similar to SARS-CoV,
MHV-2 or Ebola virus, and in contrast to other paramyxoviruses,
depends on pH- and CTSL-dependent mechanisms of entry. The
idea that NiV can use other pathways than direct fusion at the
plasma membrane was also encouraged by the recent report that
Newcastle disease virus (NDV), a prototype member of the
paramyxovirus family, can enter the cells via caveolae-mediated
endocytosis (Cantin et al., 2007). Since EB2 is a raft- and thus
caveolae-associated membrane protein (Gauthier and Robbins,
2003) and is furthermore constitutively internalized from the cell
surface, NiV might enter caveosomes via receptor-mediated
endocytosis. In support of this hypothesis, we found that EB2-
and VLP uptake was affected by MCD, an inhibitor of caveolae-
mediated endocytosis. However, MCD, sucrose or chlorproma-
zine treatment during virus entry had only a slight negative effect
on productive virus infection. This indicates that none of the
endocytic pathways is required during early virus replication
steps. Consequently, acid-dependent endosomal F cleavage by
CTSL cannot be a prerequisite for successful NiV entry. In
agreement, addition of NH4Cl or cathepsin inhibitors during early
virus replication steps did not significantly reduce the infection.
Even if these results do not rule out that endosomal entry
pathways can be an alternative route of virus entry, they clearly
show that post entry F processing in endosomes is not required for
the infectivity of NiV. Similar to paramyxoviruses with furin-
activatable F proteins such as measles or mumps virus, NiV F
cleavage occurs before virus assembly and incorporation into
budding virus particles.
In contrast to paramyxovirus F proteins which are activated by
furin, most of the surface-expressed NiV F protein is uncleaved.
Even if 60–70% of newly synthesized NiV F proteins are cleaved
within 2 h in Vero cells (compare Fig. 3A), less than 10% of the
protein found on the cell surface is proteolytically processed and
fusion active (Moll et al., 2004a). This is very likely due to an
397S. Diederich et al. / Virology 375 (2008) 391–400inefficient recycling to the plasma membrane after clathrin-
mediated uptake and CTSL cleavage of endocytosed F proteins.
Since paramyxovirus assembly is mainly directed by interactions
of the matrix protein with the cytoplasmic or transmembrane
portions of the viral glycoproteins (Peebles, 1991), proteolytic
processing of the F ectodomain has no influence on the
incorporation into budding particles. Thus, the content of cleaved
F protein in cell-free virus particles directly depends on the
amount of activated protein present in the cellular compartment
where the assembly process has taken place. The fact that despite
the low amounts of cleaved F proteins on the plasma membrane,
fully infectious NiV particles containing about 75% of cleaved
and fusion-active F proteins are released from infected cells might
indicate that NiVassembly does not occur at the cell surface but at
endosomal membranes. Fitting into this concept, the second NiV
envelope glycoprotein, the G protein is also internalized from the
cell surface (Vogt et al., 2005). The recent finding that the NiVM
protein contains a late domain motif of the YxxL type known to
interactwithAP-2, a component of the clathrin-associated adaptor
complex, andwithAIP-1/ALIX, which functions in the formation
of multivesicular bodies, a specialized endocytic compartment
(Ciancanelli and Basler, 2006; Chen et al., 2005; Irie et al., 2007;
Puffer et al., 1997), further supports the idea that endosomal
compartments are not only involved in proteolytic activation of
the F protein but might also be the site where all viral components
are recruited for virus assembly.
Together, our results clearly demonstrate that despite inter-
nalization of both, the NiV receptor and NiV particles, endo-
cytosis and a post entry cleavage mechanism are definitely not
required for the NiV entry process. Even though the proteolytic
activation of NiV F proteins clearly differs from other paramyxo-
viruses with respect to protease usage, CTSL, and the subcellular
localization where cleavage takes place, endosomes, NiV
particles released from infected cells contain sufficient amounts
of cleaved and fusion-competent F proteins to initiate the infec-
tion of new host cells by pH-independent fusion with the plasma
membrane.
Materials and methods
Cell culture and virus infection
Vero, 293T and HeLa cells were maintained in Dulbecco's
modified minimal essential medium (DMEM; Gibco) supple-
mented with 10% fetal calf serum (FCS), 100 units/ml penicillin,
and 0.1 mg/ml streptomycin. PAE (porcine aortic endothelial)
cells were grown in DMEM/F12+GLUTAMAX (Gibco) sup-
plemented with 10% FCS, penicillin and streptomycin. MDCK
(Madin–Darby canine kidney) cells were propagated in MEM
containing 10% FCS and antibiotics.
The NiV strain used in this study was isolated from human
brain (kindly provided by J. Cardosa) and propagated as
described previously (Moll et al., 2004a). For NiV infection
studies, Vero cells were infected with NiV at a multiplicity of
infection (MOI) of 0.2. After incubation for 1 h at 37 °C, virus
was removed by extensive washings and cells were cultured with
DMEMwithout FCS for 24 h at 37 °C. To prepare purified virusfor virus-uptake experiments and western blot analysis, Vero
cells were infected with NiV at a MOI of 0.001. At 48 h post
infection, supernatants were centrifuged at 4000 rpm for 10 min
at 4 °C to remove cell debris and then pelleted through a 20%
sucrose cushion at 28,000 rpm for 2 h at 4 °C in a SW28 Rotor
(Beckman). After resuspending virus pellets in buffer containing
25 mM TRIS (pH 7.5), 150 mM NaCl and 5 mM EDTA (TNE)
and a further centrifugation step at 35,000 rpm for 30 min at 4 °C
in a SW41 Rotor (Beckman), concentrated and partially purified
NiV was suspended in phosphate buffered saline (PBS) with
0.35% bovine serum albumin (BSA). All experiments with live
NiV were performed under BSL4 conditions.
Plasmids and transfection
cDNA fragments spanning the G and the F genes of the NiV
genome (GenBank™ accession number N° AF212302) were
cloned into the pczCFG5 vector as described earlier (Moll et al.,
2004b). To allow detection of the protein with commercially
available antibodies, a tagged version of the proteins was estab-
lished by inserting the amino acids YPYDVPDYA of the hu-
man influenza hemagglutinin (HA), known as HA-tag, at the
C-terminus. Expression levels and biological activity of the
HA-tagged proteins were unchanged compared to those of the
parental F and G proteins in transient transfection. The human
EB2 gene was kindly provided by D. Pfaff and H. Augustin and
subcloned into the NotI and SacI restriction sites of the
pCAGGS expression plasmid. Vero, MDCK, and HeLa cells
were transfected by using the cationic lipid transfection reagent
Lipofectamine 2000 (Invitrogen) following the instructions of
the supplier. Stably EB2-expressing PAE cells were generated
as described by Fuller et al. (2003) and kindly provided by
H. Augustin.
Preparation of NiV G-containing virus-like particles (VLPs)
VLPswere generated as described byWahl-Jensen et al. (2005).
Briefly, 293T cells were transfected with a plasmid encoding
NiV Gtag using the calcium phosphate transfection procedure
(ProFection Mammalian Transfection System, Promega). At 72 h
post transfection, supernatants were harvested, clarified from
cellular debris by centrifugation at 3000 rpm for 15min at 4 °C and
then pelleted through a 20% sucrose cushion at 30,000 rpm for 2 h
at 4 °C in a SW32 Rotor (Beckman). For washing, pellets were
suspended in PBS and again centrifuged at 30,000 rpm for 40 min
at 4 °C. Finally, VLP-containing pellets were resuspended in TNE
containing 1% BSA and were stored at −20 °C. Each VLP pre-
paration was controlled by electron microscopy and by western
blot analysis using anti-HA-tag antibodies.
EB2 uptake assay
EB2-expressing cells were grown on cover slips to sub-
confluency. Then, recombinant mouse EphB4/Fc, a soluble EB2
receptor fused to the Fc region of human IgG (R&D Systems)
was added at a concentration of 2 µg/ml. After incubation for 1 h
at 37 °C to allow binding and endocytosis to occur, surface-
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anti-human IgG antibodies (dilution 1:50; Jackson Immuno-
Research) for 90min at 4 °C. After fixation and permeabilization
with methanol–acetone, internalized EphB4/Fc was stained by
fluorescein isothiocyanate (FITC)-conjugated anti-human IgG
antibodies (dilution 1:500; Dako) for 35 min at 4 °C. Fluores-
cence images were recorded using a Zeiss Axiovert 200M
microscope.
Inhibitors
Endocytosis was inhibited by incubation with 0.45M sucrose
(Serva), 25 µM chlorpromazine (Sigma) or 5 mM β-methyl-
cyclodextrin (MCD; Sigma). Acidification of the endosome was
blocked by addition of 20 mM NH4Cl (Sigma) and cathepsin-
mediated proteolysis was prevented by the addition of either
20 µM E64d (Sigma), 20 µM CatLIII (Calbiochem) or 50 µM
CA074ME (Sigma). All chemicals and drugs were dissolved in
water or dimethylsulfoxide (E64d, CatLIII, CA074ME).
VLP uptake assay
Vero cells cultured on cover slips were pretreated with
DMEM containing 2% FCS supplemented with 0.45 M sucrose,
25 µM chlorpromazine or 5 mM β-MCD for 30 min at 37 °C.
Then, cells were incubated for 1 h at 37 °C with purified VLPs
in combination with a monoclonal antibody directed against the
HA-tag (dilution 1:200; Sigma) in the presence or absence of
the inhibitors. As control, untreated cells were incubated for 1 h
at 4 °C with VLPs and the antibody directed against the HA-tag.
Surface-bound VLPs were stained by incubation with a FITC-
conjugated anti-mouse IgG antibody (1:50; Jackson Immuno-
Research) for 90 min at 4 °C. After fixation and permeabilization
with methanol–acetone, intracellular VLPs were detected with a
rhodamine-conjugated secondary antibody (1:500; Jackson
ImmunoResearch) for 35 min at 4 °C. To visualize cell nuclei,
4′,6′-diamidino-2-phenylindole (DAPI) was added to the
secondary antibody. Representative images of merged of the
DAPI, FITC and rhodamine channels were recorded with a Zeiss
Axiovert 200M microscope.
NiV uptake assay
Vero cells grown on chamber slides (8well Permanox®Slides;
Nunc Lab-Tek) were incubated with purified NiV particles for
2 h at 4 °C. After addition of a polyclonal anti-NiV serum from
an infected guinea pig (dilution 1:1000) for 30 min on ice, cells
were washed several times to remove unbound virus and again
incubated with anti-NiV guinea pig serum and then either shifted
to 37 °C or kept at 4 °C for 20 min. Subsequently, surface-bound
viruses were stained by incubation with FITC-conjugated anti-
guinea pig antibodies (dilution 1:50; Jackson ImmunoResearch)
for 1 h at 4 °C. After fixation and permeabilization with
methanol–acetone, intracellular virus–antibody complexes
were visualized with a rhodamine-conjugated secondary anti-
body (dilution of 1:300; Jackson ImmunoResearch) for 1 h at
4 °C and cell nuclei were stained as described before. Finally,cells were incubated with 4% paraformaldehyde for 48 h and
then, image recording was performed as described above.
Metabolic labeling and immunoprecipitation of the
NiV F protein
To study the effect of the different drugs inhibiting endo-
cytosis, acidification or cathepsins on NiV F protein cleavage,
Vero cells were transfected with plasmid DNA encoding the NiV
F gene. At 24 h post transfection, cells were incubated for 40min
with medium lacking cysteine and methionine (preincubation)
followed by incubation with medium containing [35S]-cysteine
and -methionine (Promix, GE Healthcare) at a final concentra-
tion of 100 µCi for 10 min (pulse). Subsequently, labeling
medium was replaced by serum-free medium for 2 h (chase).
Inhibitors were present during preincubation, pulse and chase
periods. After metabolic labeling, cells were lysed in radio-
immunoprecipitation assay (RIPA) buffer (1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 10 mM EDTA,
10 mM iodoacetamide, 1 mM PMSF, 50 units/ml aprotinin,
20 mM Tris–HCl, pH 8.5) followed by centrifugation at
13,000 rpm for 30 min. NiV F protein was immunoprecipitated
from cell lysates with the polyclonal anti-NiV serum at a final
dilution of 1:500. After addition of 40 µl of a suspension of
protein A-Sepharose (Sigma), immune complexes were washed
three times with RIPA buffer, suspended in reducing sample
buffer, and separated on a 12% polyacrylamide gel. Dried gels
were exposed to autoradiography films (GE Healthcare).
Inhibitor studies with live NiV
To investigate the effect of inhibitors during different stages
of infection, cells were left untreated (control) or were treated
with the different chemicals or drugs inhibiting endocytosis,
acidification or cathepsin cleavage. Inhibitors were either added
1 h before infection and for 1 h during virus adsorption and
entry (Inhibitor treatment during entry) or were added 1 h after
virus entry (Inhibitor treatment after entry). NiV infection was
performed as described above. The amount of infected cells and
syncytium formation were determined by indirect immuno-
fluorescence. After fixation with 4% paraformaldehyde for 48 h
and permeabilization with methanol–acetone, cells were
incubated with the polyclonal guinea pig anti-NiV serum at a
dilution of 1:1000 for 1 h at 4 °C. Primary antibodies were then
detected with rhodamine-conjugated secondary antibodies
(dilution 1: 250). Images were recorded using a Zeiss Axiophot
microscope. Virus titers in the supernatant were determined by
the 50% tissue culture infective dose (TCID50) method on Vero
cells (Reed and Muench, 1938).
Control infections with FPV
To control the effect of inhibitors on virus entry, Vero cells were
left untreated or were treated with inhibitors for 1 h and then
inoculatedwith influenza virus A/FPV/Rostock/34 (H7N1) (FPV)
at a MOI of 0.01 in the absence or presence of the inhibitors for
1 h. After washings and inactivation of residual virus attached to
399S. Diederich et al. / Virology 375 (2008) 391–400the cell surface with DMEM adjusted to pH 3 for 5 min, cells were
further incubated at 37 °C. 16 h later, cells were fixed with
methanol–acetone and FPV-infected cells were stained with a
FPV-specific monoclonal antibody (HA1-2A11H7; kindly pro-
vided byW. Garten) at a dilution of 1:100 for 1 h at 4 °C. Primary
antibodies were detected by incubation with rhodamine-conju-
gated secondary antibodies (dilution 1:200; Jackson Immuno-
Research) and cell nuclei were visualized as described before.
Representative images were recorded using a Zeiss Axiovert
200M microscope.
Western blot analysis of purified NiV
Concentrated and partially purified NiV was inactivated and
disrupted in reducing sample buffer containing 1% SDS and
subsequently heated for 10 min at 95 °C. Pelleted supernatants of
mock infected Vero cells served as control. After separation on a
12% SDS gel, proteins were transferred to nitrocellulose. Non-
specific binding sites were blocked by 5%nonfat drymilk in PBS.
Blots were either incubated with polyclonal anti-NiV guinea pig
serum (dilution 1:500) followed by incubation with horseradish
peroxidase-conjugated rabbit anti-guinea pig immunoglobulin
(dilution 1:2000; Dako), or were probed with a F-specific anti-
body directed against amino acids 523 to 541 of the NiV F
cytoplasmic domain (dilution 1:200 in PBS; immunoGlobe
Antikörpertechnik GmbH), followed by incubation with biotin-
labeled anti-rabbit immunoglobulins (dilution 1:2000; Amer-
sham) and horseradish peroxidase-conjugated streptavidin (dilu-
tion 1:2000; Amersham). Protein bands were visualized with the
enhanced chemiluminescence system (SuperSignal®West Pico,
Pierce) by exposure to an autoradiography film (GE Healthcare).
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